愈见美乐 早瞰见 | 环丙基结构创新驱动临床双向优化，阿美替尼重塑EGFR突变NSCLC精准治疗格局
发布时间：2026-09-20 20:55 浏览量：1
*仅供医学专业人士阅读参考
阿美替尼环丙基结构支撑获益优势，绘就EGFR突变NSCLC精准治疗新图景。
参考文献
[1]Zhang L, et al. Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2026;27(2):159-168.
[2]LI Z, et al. Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial[J/OL]. The Lancet Oncology, 2026, 27(7): 785-794.
[3]Lu S, et al. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial. J Thorac Oncol. 2022;17(3):411-422.
[4]LU S, et al. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations[J/OL]. Journal of Clinical Oncology, 2022, 40(27): 3162-3171.
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场。